Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News MSD Animal Health receives EU approval for intradermal PCV vaccine

MSD Animal Health receives EU approval for intradermal PCV vaccine

9th November 2015

MSD Animal Health has announced that its new intradermal vaccine against porcine circovirus (PCV) type 2 has been approved by the European Commission.

Administered with the needle-free IDAL vaccine delivery system, the Porcilis PCV ID vaccine protects piglets starting two weeks after vaccination and offers 23 weeks of protection – the longest duration of immunity of any porcine circovirus vaccine in the EU market.

The vaccine is approved for concurrent use with Merck Animal Health’s Porcilis M Hyo ID Once, which protects piglets against Mycoplasma hyopneumoniae infections. Concurrent infection with PCV2 and M. hyo is present in the vast majority of swine operations worldwide.

Studies have shown that vaccinating piglets intradermally with Porcilis PCV ID results in uninterrupted growth during the nursery period, and improved daily weight gain and mortality associated with PCV2 infection during the fattening period.

Narciso Bento, head of MSD Animal Health's global swine business unit, said: "We are pleased to introduce the first intradermal vaccine against porcine circovirus type 2, and to expand our line of swine vaccines that can be conveniently administered with the IDAL needle-free device."

With this new launch, MSD Animal Health now offers intradermal needle-free protection against PCV2, M. hyo and porcine reproductive and respiratory syndrome virus, the three major swine diseases affecting pig operations worldwide.ADNFCR-8000103-ID-801805303-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.